Stony Plain, Canada

Jonathan Y Mane

This inventor holds 1 USPTO granted patent, plus 2 CIPO patents and 1 EPO patent. Top assignee: National Research Council of Canada. Active years: 2016.


% Patents Active = 100.0


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jonathan Y Mane in Cancer Treatment

Introduction

Jonathan Y Mane is a notable inventor based in Stony Plain, Canada. He has made significant contributions to the field of cancer treatment through his innovative research and development of colchicine derivatives. His work focuses on creating effective methods and uses of these compounds to combat cancer.

Latest Patents

Jonathan Y Mane holds a patent for "Colchicine derivatives, methods and uses thereof." This invention relates to the development of colchicine derivatives that can be utilized in the treatment of cancer. The patent outlines specific embodiments where the colchicine derivative comprises a compound of Formula I. This innovative approach aims to enhance the efficacy of cancer treatments.

Career Highlights

Mane is affiliated with the National Research Council of Canada, where he has been instrumental in advancing research in medicinal chemistry. His dedication to improving cancer therapies has positioned him as a key figure in the scientific community.

Collaborations

Throughout his career, Jonathan has collaborated with esteemed colleagues, including Jack Adam Tuszynski and John Torin Huzil. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Jonathan Y Mane's contributions to cancer treatment through his patented colchicine derivatives exemplify the impact of innovative research in medicine. His work continues to inspire advancements in therapeutic strategies for cancer patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…